Crossmark

Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan

Published Online: 2026-03-31

Authors

Yamaguchi, Kazuaki https://orcid.org/0009-0005-0494-7335
Aoki, Makoto

Osako, Ryohei
Funding

Funding for this research was provided by:

Novartis Pharma K.K.
License Information

Text and Data Mining valid from 2026-03-31

Version of Record valid from 2026-03-31
More Information

Article History

Received: 20 November 2025

Revised: 12 March 2026

Accepted: 16 March 2026

First Online: 31 March 2026

Declarations

:

: Kazuaki Yamaguchi is an employee of and owns stock in Novartis Pharma K.K. Makoto Aoki, and Ryohei Osako are employees of Novartis Pharma K.K.

Document is current